- Dallah Healthcare reported a revenue of 1.06 billion riyals for the second quarter of 2025, marking a 39% increase compared to the same period last year.
- The revenue significantly surpassed market estimates of 878.3 million riyals.
- The company’s profits rose to 124.3 million riyals, reflecting an 11% increase year-over-year.
- Operating profit for the quarter was 155.0 million riyals, which is a 9.9% rise compared to the previous year.
- The increase in revenue is attributed to the enhanced operational capacity and expansion in both existing and newly acquired medical facilities.
- Among analysts, there are 2 buy ratings, 6 hold ratings, and 4 sell ratings on the stock.
A look at Dallah Healthcare Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using Smartkarma Smart Scores indicate a positive long-term outlook for Dallah Healthcare Co. With a strong momentum score of 5, the company is showing great potential for growth and future performance. Its growth score of 4 further supports this view, suggesting promising prospects for expansion and development in the healthcare sector.
While the value and dividend scores are moderate at 3 and 2 respectively, Dallah Healthcare Co‘s resilience score of 3 highlights its ability to weather challenges and adapt to changing market conditions. Overall, the company’s profile as a provider of healthcare services in Saudi Arabia positions it well for continued growth and sustainability in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
